Optimizing Guideline-Recommended Heart Failure Treatment at Transitions of Care

Get up to date on the importance of optimizing guideline-recommended treatment in patients with heart failure at transitions of care with live webinars plus question and answer sessions with expert faculty. Watch the on-demand webcast, download the slides, and read the ClinicalThought commentary to learn more about best practices in heart failure transitions of care.

Share

Program Content

Activities

Optimizing HF Treatment at Transitions of Care
Optimizing Guideline-Recommended Heart Failure Treatment at Transitions of Care
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 03, 2023

Expires: February 02, 2024

Activities

Optimizing HF Treatment
Optimizing Guideline-Recommended Heart Failure Treatment at Transitions of Care
Video
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2023

Expires: March 12, 2024

Activities

HF Transitions
Heart Failure Transitions of Care Considerations
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 27, 2023

Faculty

cover img faculity

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

cover img faculity

Javed Butler, MD, MPH, MBA

President
Baylor Scott and White Research Institute
Dallas, Texas
Distinguished Professor of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

cover img faculity

Michelle Kittleson, MD, PhD

Professor of Medicine
Department of Cardiology
Smidt Heart Institute
Cedars-Sinai Medical Center
Los Angeles, California

Provided by

ProCE Banner
ProCE Banner

Provided by University of Cincinnati in partnership with Clinical Care Options, LLC

Supporters

This educational activity is supported by education grants from

Boehringer Ingelheim Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation